By Michael Dabaie
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said the Phase 3 Discover 1 and 2 studies, which evaluated guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis, met their primary endpoints.
The studies met the goal of American College of Rheumatology 20% improvement, and the safety profiles observed for guselkumab in the program were consistent with previous studies of guselkumab and current prescribing information, Janssen said.
Data from the two studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of guselkumab as a treatment for psoriatic arthritis, which are anticipated for later this year.
Write to Michael Dabaie at firstname.lastname@example.org